Targeted Therapies (eBook, PDF)

Mechanisms of Resistance
Redaktion: Gioeli, Daniel

• Format: PDF

Produktbeschreibung

This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included.

Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Humana Press
• Seitenzahl: 202
• Erscheinungstermin: 2. Juni 2011
• Englisch
• ISBN-13: 9781607614784
• Artikelnr.: 38328007

Inhaltsangabe

Resistance to Targeted Therapies As a Result of Mutation(s) in the Target.- The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies.- Cancer Signaling Network Analysis by Quantitative Mass Spectrometry.-

Development and Implementation of Array Technologies for Proteomics: Clinical Implications and Applications.-

Using Phosphoflow to Study Signaling Events of Sub Populations Resistant to Current Therapies.-

Mathematical and Computational Models in Cancer.-

Somatic Evolution of Acquired Drug Resistance in Cancer.-

Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer.-

MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways.- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

Mathematical and Computational Models in Cancer.-

Somatic Evolution of Acquired Drug Resistance in Cancer.-

Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer.-

MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways.- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

Mathematical and Computational Models in Cancer.-

Somatic Evolution of Acquired Drug Resistance in Cancer.-

Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer.-

MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways.- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance.

Rezensionen

From the reviews:

"This is an important resource, providing a mechanistic understanding of the signaling event in cancer for developing effective targeted cancer therapies, as well as computational biology and systems theory. ... great value to oncologists and physician-scientists treating patients, and translational scientists ... . even students interested in this field will find it useful. ... an important book for understanding major mechanisms of resistance to targeted cancer therapeutic agents as well as microRNA as a potential therapy capable of targeting multiple cancer signaling pathways." (Omer Iqbal, Doody's Review Service, September, 2011)

"The book provides a well-balanced insight into the topic of drug resistance ... . the reader can find a lot of information about the progress and inspiration how to overcome the cancer resistance. The book represents a useful source of knowledge for cell and molecular biologists, geneticists, professionals in bioinformatics, researchers and physicians working in translational oncology." (J. Sedlak, Neoplasma, Issue 6, November-December, 2012)